Potential of Lefamulin to Treat Patients with CABP Against Backdrop of Increasing Bacterial Resistance Presented on Eight Posters DUBLIN, Ireland , May 31, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 29, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
- Lefamulin met all FDA and EMA primary endpoints and was shown to be generally well tolerated - - Company plans to file a New Drug Application with the U.S. Food and Drug Administration in the fourth quarter of 2018 - - Conference call and webcast today at 8:30 a.m.
- Topline data from second pivotal Phase 3 trial of lefamulin for CABP (LEAP 2) expected in Spring 2018 - - $90 million cash and investments as of March 31, 2018 expected to fund operations into the first quarter of 2020 - DUBLIN, Ireland , May 08, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , April 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
Six abstracts support lefamulin as a potential first-in-class pleuromutilin antibiotic targeting CABP pathogens, including drug resistant phenotypes DUBLIN, Ireland , April 13, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the
DUBLIN, Ireland and HONG KONG , March 27, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of
Dr. Schranz to lead the company’s clinical development and medical affairs organization with a focus on advancing lefamulin, its lead investigational program DUBLIN, Ireland and KING OF PRUSSIA, Pa. , March 21, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage
- Positive topline results from pivotal LEAP 1 trial announced in September 2017 , with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $86.9 million cash and investments as of December 31, 2017 - DUBLIN, Ireland , March 16, 2018 (GLOBE NEWSWIRE) -- Nabriva
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , March 14, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
